PATENT CLAIM ANALYSIS

Application Number: 15875082
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["424", "133100"]

Abstract:
The present disclosure relates generally to a protocol to treat or prevent diseases or conditions associated with pathological forms of amyloid beta (Aβ), including Alzheimer's disease. Enabled herein is a reagent for use in the treatment and prophylaxis of Aβ-associated pathological conditions.

Claim (Index 1):
An isolated Fab 2286-like antibody which binds to A\u03b2 1-40  and a C-terminally elongated form thereof, said antibody comprising a modified Fab 2286 wherein a mature heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 1 with the proviso that the amino acid residue at position 50 is not glutamic acid (E), wherein the numbering of the amino acid sequence WIGE in Fab 2286 (SEQ ID NO:1) represents residues 47 to 50 or comprising one or more other amino acid substitutions, additions and/or deletions to the amino acid sequence of SEQ ID NO: 1.

Metadata:
- Claim Count in Document: 164.0
- Percentile: 86.0
- Lexical Diversity: 1.17073
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14910172', '12724343', '12788116', '15397569', '11195207']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7599295733069773
- 35 USC 102 Novelty (BERT): 0.6027852788003673
- Combined Prediction Score: 0.7442151438563164
- Mean Citation Score: 389.569902
- Max Citation Score: 613.6486
- Similarity Product: 455.1504048077703

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test